# AbbVie

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/abbvie
Canonical HTML page: https://gethealthbrief.com/entity/abbvie

## Timeline

- **2029-01-01**: Operational Launch — The North Chicago facilities are expected to begin full-scale API production.
- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-03-20**: Construction Start — Groundbreaking expected for the two new advanced manufacturing sites.
- **2026-03-04**: Earnings Release — Company reports Q4 beat and issues bullish 2026 revenue guidance.
- **2026-02-23**: Manufacturing Expansion — AbbVie announces $380M investment for North Chicago API facilities.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
- **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
- **2026**: Evolysse Launch — Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
- **2025-12-31**: Q4 Fiscal Close — Evolus concludes its strongest fiscal year to date with record Jeuveau sales.

## Recent coverage (5 stories)

### Epcoritamab Trial Misses Survival Goal—What It Means for DLBCL Patients
2026-08-01 11:31:34 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
Full story: https://gethealthbrief.com/story/epcoritamab-survival-miss-dlbcl-patient-care

### Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
2026-07-11 23:08:35 · Sentiment: Very Bullish · Impact: 8/10 · Sources: 3

A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Full story: https://gethealthbrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-60-percent-risk-reduction-health

### UCB Commits $2B to Atlanta Manufacturing Hub Amid Biologic Growth
2026-03-24 23:54:02 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
Full story: https://gethealthbrief.com/story/ucb-atlanta-2b-manufacturing-investment

### Evolus Surges on Q4 Beat as Jeuveau Gains Ground in Medical Aesthetics
2026-03-05 22:42:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
Full story: https://gethealthbrief.com/story/evolus-q4-2025-earnings-analysis-jeuveau-growth

### AbbVie Commits $380M to U.S. Manufacturing Amid $100B Domestic Pivot
2026-02-25 00:14:05 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
Full story: https://gethealthbrief.com/story/abbvie-380m-us-manufacturing-investment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.